CSIIのチャート
CSIIの企業情報
| symbol | CSII |
|---|---|
| 会社名 | Cardiovascular Systems Inc （カ―ディオバスキュラ―・システムズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 カーディオバスキュラー・システムズ(Cardiovascular Systems Inc.)は、医療技術会社であり、動脈カルシウムを含む末梢・冠動脈疾患に罹患する患者の治療に従事する。同社は、末梢・冠状動脈の両方の商用アプリケーションに、軌道アテローム切除技術を開発する。末梢動脈疾患（PAD）システムは、膝の上下の脚動脈におけるプラークタイプを治療できるカテーテルベースのプラットフォームである。同社の主力製品には、「Diamondback 360 Peripheral Orbital Atherectomy System」(OAS) (Diamondback 360 Peripheral)、「Stealth 360 OAS」(Stealth 360)、「Diamondback 360 Peripheral」、「Diamondback 360 60cm Peripheral」、「Diamondback 360 Low Profile Peripheral」、「Diamondback 360 1.50 Peripheral」及び「Diamondback 360 2.00 Peripheral」がある。同社の冠状動脈疾患（CAD）製品である「Diamondback 360 Coronary OAS」（Coronary OAS）は、重度石灰化冠状動脈の治療薬として販売される。 カ―ディオバスキュラ―・システムズは、米国の医療機器メ―カ―。血管疾患のためのインタ―ベンション治療システムの開発と商業化に焦点を当てる。末梢動脈疾患の製品、ステルス360パッドシステム、ダイヤ360パッドシステム、およびプレデタ―360パッドシステムは、カテ―テルベ―スのプラットフォ―ムで、脚の石灰化冠状動脈の治療法として使用される。 Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. |
| 本社所在地 | 1225 Old Highway 8 Northwest St. Paul MN 55112-6416 USA |
| 代表者氏名 | Scott R. Ward スコットR.ワード |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 651-259-1600 |
| 設立年月日 | 2000年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1981年 |
| 従業員数 | 652人 |
| url | www.csi360.com |
| nasdaq_url | https://www.nasdaq.com/symbol/csii |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 5.96400 |
| 終値（lastsale） | 36.45 |
| 時価総額（marketcap） | 1265033663.55 |
| 時価総額 | 時価総額（百万ドル） 1262.951 |
| 売上高 | 売上高（百万ドル） 217.04300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1167.211 |
| 当期純利益 | 当期純利益（百万ドル） 1.71200 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Cardiovascular Systems Inc revenues increased 6% to $217M. Net income totaled $1.7M vs. loss of $1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Stock-based Compensation in R&D decrease of 4% to $967K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to $0.05. |
CSIIのテクニカル分析
CSIIのニュース
Cytek Biosciences Set to Join S&P SmallCap 600 2023/04/25 21:54:00 PR Newswire
NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring…
Recent Filing Shows That Sen. Tina Smith Sold Over $100K Worth of Cardiovascular Systems Stock 2023/04/20 15:05:10 Benzinga
The Office of Senator Tina Smith has reported a sale of Cardiovascular Systems (NASDAQ: CSII ) stock on April 19, 2023. According to the April filing, the transaction was made on April 19, 2023. What Happened: A recent report from the U.S. Senate''s Office on April 19, 2023 reveals that Smith made a sale of Cardiovascular Systems stock valued between $100,002 - $200,000. Cardiovascular Systems shares are trading down 0.0% at $19.97 at the time of writing. The Importance of Congressional Transactions Congressional transactions shouldn''t be used primarily to make an investing decision, however, they can … Full story available on Benzinga.com
How should investors view Cardiovascular Systems Inc. (CSII)? 2023/02/20 18:00:00 US Post News
Within its last year performance, CSII fell by -0.71%, with highs and lows ranging from $23.47 to $12.26, whereas the simple moving average jumped by 34.36% in the last 200 days. On December 21, 2022, Barclays started tracking Cardiovascular Systems Inc. (NASDAQ: CSII) recommending Equal Weight. A report published by Lake Street on December 14, […]
Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors 2023/02/15 21:57:10 Seeking Alpha
Abbott Laboratories expands its cardiovascular pipeline with its acquisition of Cardiovascular Systems, Inc. Click here for our take on what this means for ABT.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Cardiovascular Systems, Inc. - CSII 2023/02/14 00:41:00 PR Newswire
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered…
Cardiovascular Systems, Inc. 2023 Q1 - Results - Earnings Call Presentation (NASDAQ:CSII) 2022/11/16 19:14:07 Seeking Alpha
The following slide deck was published by Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. (CSII) Q1 2023 Earnings Call Transcript 2022/11/05 17:58:03 Seeking Alpha
Cardiovascular Systems, Inc. (NASDAQ:NASDAQ:CSII) Q1 2023 Results Conference Call November 03, 2022 09:00 AM ET Company Participants Jack Nielsen - Vice President of Investor Relations…
Cardiovascular Systems GAAP EPS of -$0.27 misses by $0.04, revenue of $59.67M beats by $0.33M 2022/11/03 11:14:32 Seeking Alpha
Cardiovascular Systems press release (CSII): Q1 GAAP EPS of -$0.27 misses by $0.04.Revenue of $59.67M (+2.2% Y/Y) beats by $0.33M.Fiscal Year 2023 Guidance:Ward added, “Q1 results…
Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results 2022/11/03 11:00:00 Wallstreet:Online
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO “We are pleased with the state of
Cardiovascular Systems Q1 2023 Earnings Preview 2022/11/02 16:09:44 Seeking Alpha
Cardiovascular Systems (CSII) is scheduled to announce Q1 earnings results on Thursday, November 3rd, before market open.The consensus EPS Estimate is -$0.23 and the consensus Revenue…
Cardiovascular Systems, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:CSII) 2022/05/05 07:02:01 Seeking Alpha
The following slide deck was published by Cardiovascular Systems, Inc.
Cardiovascular Systems (CSII) Q3 2022 Earnings Call Transcript 2022/05/04 20:00:53 The Motley Fool
CSII earnings call for the period ending March 31, 2022.
Cardiovascular Systems GAAP EPS of -$0.25 beats by $0.03, revenue of $56.22M misses by $1.16M 2022/05/04 11:10:37 Seeking Alpha
Cardiovascular Systems press release (CSII): FQ3 GAAP EPS of -$0.25 beats by $0.03.Revenue of $56.22M (-11.1% Y/Y) misses by $1.16M.As of March 31, 2022, CSI had cash and…
Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results 2022/05/04 11:00:00 Business Wire
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its third quarter, ended March 31, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO “Third quarter results were in line with our expectations. Despite the impact that Omicron had on hospital capacit